𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma

✍ Scribed by John H. Farley; Kimberly W. Hickey; Jay W. Carlson; G. Scott Rose; Edward R. Kost; Terry A. Harrison


Book ID
102108236
Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
81 KB
Volume
97
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND

The objective of this study was to compare survival between patients with adenocarcinoma and patients with adenosquamous carcinoma of the cervix.

METHODS

Patients who were diagnosed with invasive cervical carcinoma from 1988 to 1999 were identified from the Automated Central Tumor Registry for the United States Military Health Care System. Clinical data, including race, age at diagnosis, histology, tumor grade, disease stage, lymph node status, treatment modality, and survival, were collected. Survival analysis was performed with Kaplan–Meier survival curves and compared using the log‐rank test.

RESULTS

A total of 273 women were identified, 185 women with a histologic diagnosis of adenocarcinoma (AC) and 88 women with a diagnosis of adenosquamous carcinoma (ASC). Among the women with ASC, only 5% had Grade 1 tumors, and 66% had Grade 3 tumors. By comparison, among the women with AC, 37% had Grade 1 tumors, and 26% had Grade 3 tumors (P < 0.001). There was no difference in the incidence of positive lymph nodes or in the number of patients who underwent radical hysterectomy as primary treatment between patients with ASC and patients with AC. More patients with ASC received radiation therapy (51% vs. 28%) or chemotherapy (29% vs. 12%) as treatment (P < 0.001). Patients who had tumors with ASC histology had a significantly decreased 5‐year survival rate compared with patients who had tumors with AC histology (65% vs. 83%; P < 0.002). When patients with early‐stage cervical carcinoma (International Federation of Gynecology and Obstetrics [FIGO] Stage I) were examined separately, there was no statistically significant difference in the 5‐year survival rate (AC, 89%; ASC, 86%; P = 0.644). However, when patients with advanced‐stage disease (FIGO Stages II–IV) were analyzed, ASC was associated with a significant decrease in median and overall survival (P = 0.01). When the results were analyzed by grade, patients who had tumors with ASC histology had a shorter survival compared with patients who had AC histology of any grade; however, this was a significant difference only for patients with Grade 1 tumors: The 5‐year survival rate for patients with Grade 1 AC was 93%, compared with 50% for patients with Grade 1 ASC (P < 0.01).

CONCLUSIONS

ASC histology appears to be an independent predictor of poor outcome in women with cervical carcinoma compared with their counterparts who have pure AC. The significant decrease in survival was observed only in patients with advanced‐stage cervical carcinoma. This decreased survival may be related mainly to the grade of ASC. Cancer 2003;97:2196–202. Published 2003 American Cancer Society.

DOI 10.1002/cncr.11371


📜 SIMILAR VOLUMES


Mucinous but not clear cell histology is
✍ Aristotle Bamias; Theodora Psaltopoulou; Maria Sotiropoulou; Dimitrios Haidopoul 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

## Abstract ## BACKGROUND: Mucinous and clear cell histology have been associated with adverse prognosis in ovarian carcinomas. The authors compared the outcome of these subtypes with that of serous tumors in patients who were treated with combination paclitaxel/platinum at their center. ## METHO

Identification of a gene-expression sign
✍ Long Huang; Min Zheng; Qing-Min Zhou; Mei-Ying Zhang; Wei-Hua Jia; Jing-Ping Yun 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB 👁 1 views

BACKGROUND: Pelvic lymph node metastasis (PLNM) is an important prognostic factor for patients with cervical carcinoma. The objective of this study was to identify a gene-expression signature that could predict PLNM in cervical carcinoma. METHODS: Eighty-eight women with cervical carcinoma with PLNM